Vaxess and GC Pharma to Collaborate on Development of Highly Effective Influenza Vaccine Smart Release Patch
Vaxess will have exclusive rights to commercialize the MIMIX Flu Smart Release Patch in the US and Europe, while GC Pharma obtains rights for the South Korean market
CAMBRIDGE, Mass. & SEOUL, South Korea–(BUSINESS WIRE)–GC Pharma, a leading manufacturer of influenza vaccines with a global reach, and Vaxess, an innovative biotechnology company developing the MIMIX smart release patch, have partnered to commercialize a highly effective, painless, and refrigeration-free flu vaccine in a new, convenient patch format.
Read the full article on BusinessWire